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Abstract
Context—Approximately 60% to 100% of women with breast cancer experience at least one 
menopausal-related symptom. Little is known about associations between menopausal status and 
symptoms in women 12 months after breast cancer surgery.
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Objective—Purpose of this study was to evaluate for differences in occurrence, severity, and 
distress of symptoms between pre- and post-menopausal women 12 months after breast cancer 
surgery.
Methods—Women with breast cancer (n=327) completed the Menopausal Symptoms Scale, that 
evaluated the occurrence, severity, and distress of 46 common menopausal-related symptoms. 
Regression analyses were used to evaluate for between group differences in the seven symptoms 
that occurred in ≥30% of the sample (i.e., hot flashes, night sweats, depression, daytime sweats, 
joint pain or stiffness, wake during the night, numbness or tingling).
Results—Of the 327 breast cancer patients who completed the 12-month assessment, 35.2% 
were premenopausal and 64.8% were postmenopausal prior to surgery. In the conditional models, 
when significant interactions were found, the differences in symptom occurrence rates between 
pre- and postmenopausal patients depended on their age.
Conclusions—Regardless of menopausal status, women reported relatively high occurrence 
rates for several menopausal symptoms. Associations between symptom occurrence rates and 
menopausal status depended on the patient’s age.
Implications for Practice—During the development of a survivorship care plan, clinicians 
need assess symptom burden within the context of a woman’s menopausal status and salient 
demographic and clinical characteristics. This approach will assist with the prescription of more 
effective interventions.
Keywords
symptoms; premenopausal; postmenopausal; breast cancer; surgery
INTRODUCTION
Between 65% and 100% of women with breast cancer experience at least one treatment-
induced, menopausal-related symptom.1,2 These symptoms include: sleep disturbance, 
musculoskeletal pain, mood changes, vasomotor symptoms, sexual dysfunction, vaginal 
dryness and atrophy, cognitive impairment, headaches, weight gain, and fatigue.3,4 These 
menopausal-related symptoms are some of the most common and distressing side effects of 
breast cancer treatment.2,5 Moreover, because of abrupt changes in sex steroid hormones, 
these symptoms are often more frequent and severe than those experienced during a natural 
menopausal transition.6 For premenopausal women, this unexpected exacerbation of 
symptoms can have a negative impact on their quality of life (QOL).6,7
The occurrence, severity, and distress from these menopausal-related symptoms vary based 
on a woman’s menopausal status;8–10 age;4,11 type of cancer treatment (i.e., chemotherapy 
(CTX), endocrine therapy (ET));12,13 and time since completion of treatment; as well as 
demographic, health and illness, and psychosocial factors.12 For example, following breast 
cancer treatment, compared to postmenopausal patients, women who were premenopausal at 
diagnosis reported more severe vasomotor symptoms,14 sexual dysfunction,15 and sleep 
disturbances.14 In addition, in another study,16 the highest menopausal-related symptom 
burden was reported in the first six months after the completion of primary treatment.
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While, the impact of menopausal-related symptoms is well documented,1,2,5,12,17–19 little is 
known about differences in the occurrence, severity, and distress of these symptoms between 
premenopausal and postmenopausal women one year after breast cancer surgery. The 
majority of these studies compared differences in the symptom experience of older versus 
younger women;4,11,20 younger women who did or did not experience treatment-induced 
menopause;1,2,10 and/or specific types of treatment (i.e., CTX, tamoxifen, aromatase 
inhibitors (AIs)).12,13,21–24 Moreover, the majority of these studies evaluated a single 
symptom; a single dimension of the symptom experience; included women several years 
after a breast cancer diagnosis; and/or did not evaluate the impact of menopausal status on 
differences in patients’ symptom experiences. (for reviews see1, 3, 10) In fact, to our 
knowledge, only five studies reported on differences in menopausal-related symptoms 
between pre- and postmenopausal women after primary breast cancer treatment.8,9,14,15,25
These five studies evaluated for associations between pre-diagnosis menopausal status and 
symptom occurrence8,9,25 or severity14,15 in women who had received adjuvant CTX and/or 
ET. Two longitudinal studies evaluated symptom severity before and immediately after 
CTX.28,29 Three cross-sectional studies evaluated menopausal symptom occurrence six 
months21 to several years7,27 after diagnosis. Compared to postmenopausal patients, 
premenopausal women reported higher occurrence rates of hot flashes, night sweats,8,9,25 
vaginal dryness, and libido reduction.8 In one study,8 while two-thirds of the menopausal-
related symptoms were reported as severe by premenopausal women, differences in severity 
scores between pre- and postmenopausal women were not evaluated.
Findings from these five studies provide preliminary evidence of differences in the 
occurrence8,9,25 and severity14,15 of menopausal-related symptoms based on pre-diagnosis 
menopausal status. However, a number of limitations warrant consideration. These studies 
evaluated only a single symptom14 and/or one dimension of the symptom experience.
8,9,14,15,25
 Two studies did not include relevant covariates such as body mass index (BMI) in 
their analysis.8,25 In two studies, the assessments were done either several years after the 
cancer diagnosis25 or the time since diagnosis was not reported.8 In addition, in two studies,
14,15
 the sample sizes of premenopausal women were relatively small. If differences were 
found in the symptom experience of pre- versus postmenopausal women after surgery, this 
information could be used to guide symptom management interventions.
Given the paucity of research on the association between menopausal status prior to surgery 
and menopausal-related symptoms after primary breast cancer treatment, the purpose of this 
study was to evaluate for differences in multiple dimensions of the symptom experience (i.e., 
occurrence, severity, distress) between pre- and postmenopausal women one year after breast 
cancer surgery. We hypothesized that both groups of women would report the co-occurrence 
of multiple menopausal-related symptoms. In addition, we hypothesized that compared to 
postmenopausal women, women who were premenopausal at diagnosis would report higher 
occurrence rates of and severity and distress ratings for vasomotor symptoms (i.e., hot 
flashes, night sweats, daytime sweats).
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METHODS
The methods for the larger descriptive, longitudinal study that evaluated neuropathic pain 
and lymphedema in women who underwent breast cancer surgery are described in detail 
elsewhere.26–30 In brief, women were recruited from seven Breast Cancer Centers in 
Northern California. Women were eligible if they: were ≥18 years of age; were scheduled 
for unilateral breast cancer surgery; were able to read, write, and understand English; agreed 
to participate; and provided written informed consent. Patients were excluded if they had 
bilateral breast surgery and/or had distant metastases at the time of diagnosis.
Instruments
Patients completed a demographic questionnaire, the Karnofsky Performance Status (KPS) 
scale,31 and the Self-Administered Comorbidity Questionnaire (SCQ).32 Menopausal status 
was determined by the patient’s response (yes/no) at the time of study enrollment to the 
question “Have you gone through menopause yet (stopped having your menstrual cycle)?”.
The Menopausal Symptoms Scale (MSS), that was modified from the Seattle Women’s 
Health Study questionnaire,33 was used to evaluate the occurrence, severity, and distress of 
46 menopausal-related symptoms. Women were asked to indicate whether they experienced 
each symptom during the past week (i.e., symptom occurrence). If they experienced the 
symptom, they were asked to rate its severity and distress. Symptom severity was rated on a 
0 (‘none’) to 10 (‘intolerable’) numeric rating scale (NRS). Symptom distress was rated on a 
0 (‘not at all distressing’) to 10 (‘very distressing’) NRS. The MSS has well established 
validity and reliability.34
Study Procedures
The study was approved by the Committee on Human Research at the University of 
California, San Francisco and by the Institutional Review Boards at each of the study sites. 
A clinician explained the study, determined the woman’s willingness to participate, and 
introduced her to the research nurse. All patients provided written informed consent. Women 
completed the enrollment questionnaire an average of four days prior to surgery. For the 
current study, data from the KPS, SCQ, and MSS that were obtained one year after surgery 
were analyzed. Medical records were reviewed for disease and treatment information.
Statistical Analysis
Data were analyzed using SPSS Version 23 (IBM, Armonk, NY). Descriptive statistics and 
frequency distributions were generated on sample characteristics and symptom occurrence 
rates, severity scores, and distress scores. Using their self-reported status, women were 
categorized into the premenopausal and postmenopausal groups at enrollment (i.e., prior to 
surgery). Independent Student t-tests, Mann-Whitney U tests, Fisher Exact tests, and Chi 
Square analyses were used to evaluate for differences in demographic and clinical 
characteristics between the two menopausal groups. Characteristics that differed 
significantly between the menopausal groups were considered for use as potential covariates 
in the logistic and linear regression analyses.
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As part of the evaluation of between group differences, symptom occurrence rates were 
generated for each symptom and mean scores for severity and distress ratings were 
calculated for patients who reported a symptom. Unadjusted and adjusted logistic regression 
analyses were used to evaluate for between group differences in symptom occurrence rates. 
For symptoms that occurred in ≥30% of the total sample, unadjusted and adjusted linear 
regression analyses were used to evaluate for between group differences in symptom severity 
and distress scores. First, menopausal status was entered into the regression analysis 
(unadjusted model). Then, characteristics that were found to be significantly different 
between the two menopausal groups and identified as potential covariates were added into 
the model along with menopausal status (adjusted model). Finally, the interaction between 
age and menopausal status group was evaluated. If the age by menopausal status group 
interaction was statistically significant, an adjusted stratified analysis was done for 
premenopausal and postmenopausal women.35 The stratified analyses were done because the 
interaction term was significant, but the sample size was too small to generate stable 
combined estimates. A p-value of <.05 was considered statistically significant.
RESULTS
Differences in demographic characteristics
Of the 327 women with breast cancer who completed the 12-month assessment, 35.2% were 
premenopausal and 64.8% were postmenopausal prior to surgery. Compared to 
postmenopausal women, premenopausal women were significantly younger, were less likely 
to live alone, and were more likely to be employed (Table 1).
Differences in clinical characteristics
Compared to postmenopausal women, premenopausal women had a lower SCQ score. In 
addition, a lower percentage of premenopausal women reported high blood pressure, 
diabetes, ulcer, osteoarthritis, a prior hysterectomy, a prior oophorectomy, were on HRT 
prior to surgery, and had external beam radiation therapy (RT) during the prior 12 months. A 
higher percentage of premenopausal women had a mastectomy versus conservation surgery, 
had breast reconstruction during the prior 12 months, received adjuvant CTX during the 
prior 12 months, and had undergone genetic testing for BRCA1 and BRCA2 (Table 1).
Differences in symptom occurrence rates and total number of symptoms
Occurrence rates for the 46 symptoms on the MSS and for the top ten occurring symptoms 
are listed in the Supplementary Table 1 and in Table 2, respectively. No differences were 
found in the total number of symptoms reported by premenopausal versus postmenopausal 
women. The five symptoms with the highest occurrence rates in premenopausal women 
were: wake during the night, hot flashes, fatigue or tiredness, difficulty falling asleep, and 
night sweats. While wake during the night, fatigue or tiredness and hot flashes, were among 
the 5 most common symptoms in the postmenopausal group, they reported two different 
symptoms (i.e., joint pain or stiffness and waking too early).
Unadjusted and adjusted analyses of symptoms with higher occurrence rates 
in premenopausal women—As shown in Table 3, in the unadjusted models, 
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premenopausal patients reported higher occurrence rates for eating more than usual, skin 
breakout/acne, hostility, weight gain, irritability, and lost sexual interest. In the multivariate 
analyses, after adjusting for nine covariates, no differences in these symptoms’ occurrence 
rates were found between the two menopausal groups.
Unadjusted and adjusted analyses of symptoms with higher occurrence rates 
in postmenopausal women—In the unadjusted and adjusted analyses, none of the 
symptom occurrence rates were significantly higher in the postmenopausal group.
Differences in occurrence rates for symptoms with interaction effects—As 
shown in Table 4, in the unadjusted models, premenopausal women reported higher 
occurrence rates for hot flashes, night sweats, depression, and daytime sweats. 
Postmenopausal women reported higher occurrence rates for joint pain or stiffness.
In the adjusted models that evaluated seven symptoms for which significant interactions 
were found between age and menopausal status (i.e., hot flashes, night sweats, depression, 
daytime sweats, joint pain or stiffness, wake during the night, numbness or tingling), the 
differences in symptom occurrence rates between pre- and post-menopausal women 
depended on their age. In the premenopausal group, as age increased, women were 
significantly more likely to report depression and joint pain or stiffness. In the 
postmenopausal group, as age increased, women were significantly less likely to report hot 
flashes, night sweats, depression, daytime sweats, wake during the night, and numbness or 
tingling.
Differences in symptom severity scores
The severity scores for the 46 as well as for the ten symptoms with the highest mean severity 
scores are listed in the Supplementary Table 1 and in Table 2, respectively. For 
premenopausal women, the five symptoms with the highest severity scores were: cramps, 
diarrhea, lost sexual interest, fatigue or tiredness, and mood swings. While lost sexual 
interest and cramps were among the five most severe symptoms in the postmenopausal 
group, they reported three different symptoms (i.e., abdominal bloating, vaginal dryness, hot 
flashes).
Unadjusted and adjusted analyses of symptoms with higher severity scores 
in premenopausal women—As shown in Table 5, in the unadjusted models for 
symptoms that occurred in >30.0% of the sample, premenopausal women reported higher 
symptom severity scores for impatience and irritability. In the adjusted analysis, 
premenopausal women reported higher symptom severity scores for fatigue.
Unadjusted and adjusted analyses of symptoms with higher severity scores 
in postmenopausal women—In the unadjusted and adjusted analyses, none of the 
severity scores were significantly higher in the postmenopausal group.
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Differences in symptom distress scores
The distress scores for the 46 symptoms, as well as for the ten symptoms with the highest 
mean distress scores, are listed in the Supplementary Table 1 and in Table 2, respectively. 
For premenopausal women, the five symptoms with the highest distress scores were: weight 
gain, diarrhea, swollen hands/feet, hostility, and tearful/crying spells. While weight gain was 
one of the five most distressing symptoms in the postmenopausal women, they reported four 
different symptoms (i.e., lost sexual interest, cramps, abdominal bloating, eating more than 
usual).
Unadjusted and adjusted analyses of symptoms with higher distress scores 
in premenopausal women—As shown in Table 5, in the unadjusted analyses for 
symptoms that occurred in >30% of the sample, premenopausal women reported higher 
distress scores for impatience. In the adjusted analyses, none of the distress scores were 
significantly higher in premenopausal women.
Unadjusted and adjusted analyses of symptoms with higher distress scores 
in postmenopausal women—In the unadjusted and adjusted analyses, none of the 
symptom distress scores were significantly higher in the postmenopausal women.
DISCUSSION
This study is the first to describe associations between preoperative menopausal status and 
symptom occurrence, severity, and distress in women one year after breast cancer surgery. 
Consistent with previous studies,1,2,4,36 our first hypothesis was supported. All women, 
regardless of menopausal status, reported an average of 11 co-occurring symptoms (range of 
0 to 38). Our second a priori hypothesis was only partially supported. After accounting for 
multiple demographic, clinical, and treatment characteristics, the relationship between 
menopausal status and the occurrence rates for vasomotor symptoms was dependent on 
women’s age. In terms of severity, fatigue was the only symptom that was more severe in 
premenopausal women. Of note, no differences in symptom distress ratings were found 
between the menopausal groups.
Findings from this study have a number of clinical implications. For example, our findings 
suggest that women who used HRT prior to their breast cancer diagnosis were two to three 
times more likely to report vasomotor symptoms even one year after stopping the 
medication. Therefore, previous use of HRT should be assessed as part of survivorship care. 
Given the large number of symptoms and dimensions evaluated, the discussion will focus 
primarily on significant differences in symptom dimensions found between pre- and 
postmenopausal women and the interaction of age and menopausal status.
Symptom Occurrence
Differences in the occurrence of symptoms with interaction effects—One of the 
strengths of this study is that for each of the symptoms, after controlling for clinically 
meaningful characteristics, the interaction between menopausal status and age was 
evaluated. For example, significant interactions were found between age and menopausal 
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status for all three vasomotor symptoms (i.e., hot flashes, night and daytime sweats). While 
this specific interaction was not reported previously, relative to younger and older 
premenopausal women, it is common for older premenopausal and younger postmenopausal 
women to report vasomotor symptoms.36,37 Similarly, in our study, as premenopausal 
women aged, they were 25% to 48% less likely to report vasomotor symptoms. However, 
contrary to previous findings,1 as premenopausal women’s age increased, they did not report 
higher occurrence rates for vasomotor symptoms. Our sample size may have been too small 
to detect the effects of age on the occurrence of hot flashes in our premenopausal women.
While the occurrence of nighttime awakenings was the most common symptom in both pre- 
and postmenopausal women, a significant interaction was found between menopausal status 
and age. While no studies evaluated for interaction effects, in previous reports, pre- and 
postmenopausal women differed on post-treatment occurrence rates for restless sleep10 and 
insomnia.8 Moreover, consistent with prior reports,15 none of the other covariates in the 
multivariate analysis predicted variations in the occurrence of wake during the night. Given 
the high occurrence rates of nighttime awakenings in women with and without breast cancer, 
the causes for this symptom warrant additional investigation so that appropriate 
interventions can be prescribed.15
Numbness and tingling are associated with the neurotoxic effects of CTX.38 Therefore, it is 
not surprising that women in our study who were treated with CTX in the past 12 months 
were 2.5 times more likely to report this symptom. Given that numbness and tingling can be 
related to hormonal changes during menopause39 and/or the neurotoxicity of CTX,38 the 
etiology of these symptoms warrant evaluation in future studies.
Symptom Severity
Fatigue was the only symptom that was more severe in premenopausal women and in 
women with a higher level of comorbidity. Consistent with a previous report,40 
premenopausal women were more likely to report the occurrence as well as more severe 
fatigue after CTX and during the first three years of hormone therapy. Given that fatigue is 
common, moderately severe, persists over time,19 and may be associated with a higher 
symptom burden,41 it warrants ongoing assessment and management.
While we hypothesized that premenopausal women would report higher severity scores for 
vasomotor symptoms, our findings are not consistent with previous reports. In previous 
studies, compared to postmenopausal women with breast cancer, premenopausal women 
reported more severe vasomotor symptoms15 and hot flashes14 after CTX and were more 
likely to report severe hot flashes while taking tamoxifen.25 These inconsistent findings may 
be related to differences in how symptoms were assessed and categorized, the timing of the 
assessments, and failure to control for significant covariates in the analyses.
The ranking of the five most severe symptoms differed by menopausal group. Moreover, 
regardless of menopausal status, the ten most severe symptoms were in the moderate 
severity range. In fact, for the entire sample, using a moderate cutoff score of >4.0,42 13 of 
the 46 symptoms were in the moderate to severe range. A survivorship care plan, that 
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includes aggressive symptom management interventions, is warranted after surgery to 
prevent the escalation of symptoms during the subsequent year.
Symptom Distress
No between group differences in symptom distress scores were identified. In contrast, 
previous reports suggested that younger women were more bothered by menopausal 
symptoms than older women.21,43–45 For example, compared to women older than 60, 
younger women reported that vasomotor symptoms, vaginal symptoms, and weight 
problems were more bothersome.21 However, the influence of menopausal status was not 
evaluated in this study.
In our study, the analysis of severity and distress ratings included only those women who 
reported the occurrence of the symptom. The exclusion of women who did not experience 
the symptom provides a more accurate evaluation of the impact of each symptom.3 However, 
in most of the previous studies, the analyses included women who did not have the 
symptom. In addition, one of the most common instruments used to evaluate menopausal-
related symptoms in breast cancer patients is the Breast Cancer Prevention Trial (BCPT) 
checklist.4,46 The BCPT assesses “bother” using a 0 “not at all” to 4 “extremely” Likert 
scale. While this instrument is valid and reliable,46 the term “bother” is used interchangeably 
with “severity”,10,21 “intensity”,47 and “distress”.48 These differences make comparisons of 
severity and distress scores across studies difficult.
Similar to severity, the rankings of the five most distressing symptoms differed by 
menopausal status. Regardless of menopausal status, many of the ten most distressing 
symptoms were in the moderate range. While both menopausal groups reported 
approximately 11 symptoms, premenopausal women reported a higher number of distressing 
symptoms. This difference highlights the importance of comprehensive assessments of all 
symptom dimensions in women after breast cancer treatment.
Limitations
Several limitations warrant consideration. The woman’s self-report of menopausal status at 
diagnosis was used to create the two groups. Moreover, the inclusion of five women who 
were on HRT in the premenopausal group suggests that some women may have been 
perimenopausal. While the gold standard for determining menopausal status includes an 
assessment of menstrual cycle, hormonal levels, and symptoms,49 previous studies support 
the validity and reliability of self-report.18,50 Moreover, while menopausal status was not re-
evaluated at 12 months, this study’s aim was to compare pre-surgical menopausal status and 
women’s symptom experience at 12 months after surgery. In addition, testing for 
interactions between age and menopausal status accounted for variations between younger 
and older pre- and postmenopausal women. Some of the symptoms on the MSS (e.g., 
cramps) may be interpreted differently by pre- (i.e., menstrual cramps) versus post- (i.e., 
gastrointestinal cramps) menopausal women. Lastly, the majority of women in this study 
was Caucasian and well educated, which limits the generalizability of our findings.
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Implications for Clinical Practice and Research
Regardless of menopausal status, at one year following surgery, our patients experienced 
multiple co-occurring symptoms that were in the moderate to severe range for both severity 
and distress. Moreover, similar to previous reports of women after breast cancer treatment,
2,10,11
 the occurrence of menopausal-related symptoms varied based on menopausal status, 
as well as demographic (e.g., age), clinical (e.g., level of comorbidity), and treatment (e.g., 
prior HRT use, receipt of adjuvant CTX in prior 12 months) characteristics. Of note, all of 
the differences in symptom occurrence rates depended on the interaction between age and 
menopausal status. Accordingly, both characteristics warrant consideration during the 
assessment of symptom burden. Given that these menopausal symptoms negatively impact 
women’s well-being after primary breast cancer treatment, assessment and education prior 
to and during therapy may help manage expectations of symptom burden over time. Findings 
from this study can be used by clinicians to focus their assessments and individualize patient 
education and interventions.
Given the various etiologies for menopausal-related symptoms, longitudinal evaluations of 
how symptoms change from pre- to post-treatment are warranted. These time-sensitive 
evaluations may identify other causal associations between menopausal status and symptom 
burden (e.g., pre-surgical anxiety). Moreover, studies of the inter-relationships among 
symptoms (i.e., symptom clusters) using multiple dimensions of the symptom experience are 
warranted. Increased information on menopausal symptom clusters could be used to support 
future studies on the common and distinct mechanisms that underlie these symptom clusters, 
well as interventions to manage single and multiple menopausal-related symptoms.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Differences in demographic and clinical characteristics between premenopausal and postmenopausal women 
12 months after breast cancer surgery
Demographic characteristics Premenopausal
n=115 (35.2%)
Postmenopausal
n=212 (64.8%)
Statistics
Mean (SD) Mean (SD)
Age (years) 45.2 (6.2) 61.0 (10.4) t=−17.21; p<.001
Education (years) 15.9 (2.4) 15.6 (2.8) t=1.04; p=.296
% (n) % (n)
Ethnicity
FE; p=.328 White 63.5 (73) 68.9 (146)
 Non-white 36.5 (42) 31.1 (66)
Lives alone (% yes) 13.9 (16) 28.4 (60) FE; p=.004
Married/partnered (% yes) 35.7 (41) 44.8 (95) FE; p=.127
Currently working for pay (% yes) 60.5 (69) 44.5 (94) FE; p=.007
Total annual household income
U; p=.150
 < $10,000 to $19,999 6.9 (7) 5.4 (9)
 $20,000 to $99,000 47.5 (48) 59.9 (100)
 ≥ $100,000 45.5 (46) 34.7 (58)
Clinical characteristics Mean (SD) Mean (SD)
Body mass index (kg/m2) 25.9 (5.6) 27.1 (6.1) t=−1.82; p=.069
Karnofsky Performance Status score 94.2 (9.8) 93.6 (10.0) t=0.50; p=.620
Self-Administered Comorbidity Scale score 3.1 (2.2) 4.4 (3.4) t=−4.02; p<.001
Number of menopausal symptoms 12.0 (8.7) 10.3 (8.0) t=1.83; p=.068
Months since diagnosis 13.6 (2.9) 13.8 (2.3) t=−0.52; p=.601
% (n) % (n)
Occurrence of comorbid conditions (% and number of women who reported each 
comorbid condition from the Self-Administered Comorbidity Questionnaire)
 Heart disease 1.7 (2) 5.7 (12) FE; p=.150
 High blood pressure 14.8 (17) 38.7 (81) FE; p<.001
 Lung disease 1.7 (2) 2.4 (5) FE; p=1.000
 Diabetes 1.7 (2) 12.7 (27) FE; p<.001
 Ulcer 0.0 (0) 5.2 (11) FE; p=.010
 Kidney disease 0.0 (0) 0.0 (0) FE; p=1.00
 Liver disease 0.0 (0) 1.9 (4) FE; p=.302
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Demographic characteristics Premenopausal
n=115 (35.2%)
Postmenopausal
n=212 (64.8%)
Statistics
Mean (SD) Mean (SD)
 Anemia 5.2 (6) 4.3 (9) FE; p=.783
 Depression 13.0 (15) 16.5 (35) FE; p=.427
 Osteoarthritis 9.6 (11) 22.2 (47) FE; p=.004
 Back pain 22.6 (26) 24.1 (51) FE; p=.787
 Rheumatoid arthritis 3.5 (4) 5.2 (11) FE; p=.588
Diagnosed with mastitis (% yes) 13.0 (15) 12.7 (27) FE; p=1.000
Diagnosed with fibrocystic disease (% yes) 15.8 (18) 23.4 (48) FE; p=.115
Exercise on a regular basis (% yes) 77.4 (89) 73.5 (155) FE; p=.525
Ever breast fed (% yes) 50.4 (58) 43.4 (92) FE; p=.246
Prior hysterectomy (% yes) 4.3 (5) 17.9 (38) FE; p<.001
Prior oophorectomy (% yes) 4.3 (5) 13.7 (29) FE; p=.008
Type of surgery
 Breast conservation 72.2 (83) 84.4 (179) X2; p=.009
 Mastectomy 27.8 (32) 15.6 (33)
Sentinel lymph node biopsy (% yes) 86.1 (99) 84.0 (178) FE; p=.748
Axillary lymph node dissection (% yes) 35.1 (40) 31.6 (67) FE; p=.538
Re-excision or mastectomy during the 12 months (% yes) 33.9 (39) 27.4 (58) FE; p=.254
Breast reconstruction during the 12 months (% yes) 20.9 (24) 9.0 (19) FE; p=.003
Received neoadjuvant chemotherapy (% yes) 15.8 (18) 19.8 (42) FE; p=.454
Received adjuvant chemotherapy during the 12 months (% yes) 42.6 (49) 28.3 (60) FE; p=.010
Received external beam radiation therapy during the 12 months (% yes) 65.2 (75) 76.9 (163) FE; p=.027
On hormonal therapy during the 12 months (% yes) 65.2 (75) 62.3 (132) FE; p=.632
On HRT prior to surgery (% yes) 4.4 (5) 24.6 (52) FE; p<.001
Stage of disease
U; p=.264
 Stage 0 21.6 (25) 18.0 (38)
 Stage I 41.4 (48) 39.3 (83)
 Stage IIA and IIB 31.9 (37) 35.5 (75)
 Stage IIIA, IIIB, IIIC, and IV 5.2 (6) 7.1 (15)
Estrogen receptor positive (% yes) 78.3 (90) 76.8 (162) FE; p=.784
Progesterone receptor positive (% yes) 77.4 (89) 67.3 (142) FE; p=.057
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Demographic characteristics Premenopausal
n=115 (35.2%)
Postmenopausal
n=212 (64.8%)
Statistics
Mean (SD) Mean (SD)
HER2/neu receptor positive (% yes) 16.5 (17) 16.9 (32) FE; p=1.000
BRCA1 and BRCA2 genetic testing
X2=10.78; p=.004
 Positive 2.6 (3) 1.0 (2)
 Negative 18.4 (21) 7.2 (15)
 Not done 78.9 (90) 91.9 (192)
Abbreviations: BRCA = breast cancer; FE = Fisher’s Exact; HER2/neu = human epidermal growth factor receptor 2; HRT = hormone replacement 
therapy; kg = kilogram; m2 = meters squared; SD = standard deviation; U = Mann Whitney U test
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Table 2
Differences between premenopausal and postmenopausal women in rankings of symptoms with the highest 
occurrence, severity, and distress ratings 12 months after breast cancer surgery
Occurrence Rates
Rank
Premenopausal
% of women
Postmenopausal
% of women
Symptom Symptom
1 Wake during the night 61.7 Wake during the night 63.7
2 Hot flashes 58.3 Joint pain or stiffness 51.9
3 Fatigue or tiredness 54.8 Fatigue or tiredness 50.0
4 Difficulty falling asleep 44.3 Hot flashes 45.3
5 Night sweats 44.3 Waking too early 42.9
6 Impatience 43.5 Difficulty falling asleep 42.0
7 Irritability 41.7 Backache or neckache 35.8
8 Waking too early 41.7 Impatience 34.4
9 Anxiety 40.9 Night sweats 32.5
10 Backache or neckache 40.9 Anxiety 31.6
Severity Rating+
Rank Symptom Mean (SD) Symptom Mean (SD)
1 Cramps 5.1 (2.5) Lost sexual interest 6.2 (2.6)
2 Diarrhea 5.0 (3.0) Cramps 4.6 (2.8)
3 Lost sexual interest 4.7 (2.6) Abdominal bloating 4.6 (2.7)
4 Fatigue or tiredness 4.7 (2.6) Vaginal dryness 4.6 (2.9)
5 Mood swings 4.5 (2.8) Hot flashes 4.4 (2.1)
6 Hot flashes 4.4 (2.5) Night sweats 4.3 (2.0)
7 Headache 4.4 (2.6) Joint pain or stiffness 4.2 (2.3)
8 Backache or neckache 4.3 (2.9) Difficulty falling asleep 4.2 (2.6)
9 Daytime sweats 4.3 (2.4) Daytime sweats 4.2 (1.8)
10 Joint pain or stiffness 4.3 (2.3) Wake during the night 4.1 (2.5)
Distress Rating++
Rank Symptom Mean (SD) Symptom Mean (SD)
1 Weight gain 5.1 (3.3) Lost sexual interest 5.6 (3.4)
2 Diarrhea 5.1 (3.8) Cramps 5.3 (3.3)
3 Swollen hands/feet 4.9 (2.9) Abdominal bloating 4.8 (3.7)
4 Hostility 4.8 (3.2) Weight gain 4.4 (3.4)
5 Tearful/crying spells 4.5 (2.9) Eating more than usual 4.2 (3.1)
6 Anger 4.5 (3.0) Joint pain or stiffness 4.0 (2.7)
7 Mood swings 4.5 (3.2) Panic feelings 4.0 (2.3)
8 Anxiety 4.3 (3.0) Difficulty falling asleep 4.0 (2.8)
9 Headache 4.2 (3.0) Depression 3.9 (2.9)
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Occurrence Rates
Rank
Premenopausal
% of women
Postmenopausal
% of women
Symptom Symptom
10 Nausea/upset stomach 4.2 (3.0) Vaginal dryness 3.9 (2.9)
Abbreviation: SD = standard deviation
+Symptom severity scores ranged from 0 (none) to 10 (intolerable).
++Symptom distress scores ranged from 0 (not at all distressing) to 10 (very distressing).
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 19
Ta
bl
e 
3
R
es
ul
ts 
of
 u
na
dju
ste
d a
nd
 ad
jus
ted
 lo
gis
tic
 re
gr
es
sio
n 
an
al
ys
es
 th
at
 ev
al
ua
te
d 
fo
r d
iff
er
en
ce
s i
n 
sy
m
pt
om
 o
cc
ur
re
nc
e 
ra
te
s b
et
w
ee
n 
pr
em
en
op
au
sa
l a
nd
 
po
stm
en
op
au
sa
l w
o
m
en
 1
2 
m
on
th
s a
fte
r b
re
as
t c
an
ce
r s
ur
ge
ry
SY
M
PT
O
M
 O
C
C
U
R
R
EN
C
E
LO
G
IS
TI
C
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
O
cc
ur
re
n
ce
 r
a
te
 %
C
ov
a
ri
at
e
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
PR
E
(n
=1
15
)
PO
ST
(n
=2
12
)
O
R
C
I
p-
va
lu
e
O
R
C
I
p-
va
lu
e
Ea
tin
g 
m
or
e 
th
an
 u
su
al
25
.0
12
.3
O
ve
ra
ll 
M
od
el
X
2 =
19
.3
3;
 p
=.
03
6
M
en
op
au
sa
l s
ta
tu
s*
0.
41
0.
23
, 0
.7
5
.
00
4
0.
43
0.
19
, 1
.0
0
.
05
0
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
0.
95
0.
79
, 1
.1
4
.
56
5
Li
v
es
 a
lo
ne
0.
72
0.
32
, 1
.6
2
.
42
9
W
o
rk
in
g 
fo
r p
ay
0.
75
0.
4,
 1
.4
2
.
38
4
SC
Q 
sco
re
1.
13
1.
00
, 1
.2
6
.
04
4
Pr
io
r H
RT
0.
86
0.
32
, 2
.2
8
.
76
1
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
1.
30
0.
68
, 2
.4
7
.
42
5
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
1.
33
0.
58
, 3
.0
1
.
50
1
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
0.
85
0.
29
, 2
.4
9
.
77
1
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
2.
08
0.
82
, 5
.2
7
.
12
5
Sk
in
 b
re
ak
o
u
t/a
cn
e
17
.2
7.
1
O
ve
ra
ll 
M
od
el
X
2 =
24
.1
1;
 p
=.
00
7
M
en
op
au
sa
l s
ta
tu
s*
0.
39
0.
19
, 0
.7
9
.
00
9
1.
00
0.
38
, 2
.6
6
.
99
9
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
0.
71
0.
56
, 0
.8
9
.
00
3
Li
v
es
 a
lo
ne
2.
58
1.
09
, 6
.1
.
03
1
W
o
rk
in
g 
fo
r p
ay
1.
33
0.
6,
 2
.9
2
.
48
0
SC
Q 
sco
re
1.
06
0.
91
, 1
.2
4
.
45
0
Pr
io
r H
RT
0.
71
0.
18
, 2
.6
9
.
61
0
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
1.
12
0.
51
, 2
.4
5
.
78
6
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
0.
73
0.
29
, 1
.8
6
.
51
4
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
1.
40
0.
43
, 4
.5
9
.
57
7
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
1.
20
0.
39
, 3
.6
8
.
74
5
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 20
SY
M
PT
O
M
 O
C
C
U
R
R
EN
C
E
LO
G
IS
TI
C
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
O
cc
ur
re
n
ce
 r
a
te
 %
C
ov
a
ri
at
e
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
PR
E
(n
=1
15
)
PO
ST
(n
=2
12
)
O
R
C
I
p-
va
lu
e
O
R
C
I
p-
va
lu
e
H
os
til
ity
16
.5
7.
1
O
ve
ra
ll 
M
od
el
X
2 =
15
.1
2;
 p
=.
12
8
M
en
op
au
sa
l s
ta
tu
s*
0.
38
0.
19
, 0
.7
9
.
00
9
0.
59
0.
23
, 1
.5
4
.
28
4
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
0.
77
0.
62
, 0
.9
6
.
02
1
Li
v
es
 a
lo
ne
0.
96
0.
36
, 2
.5
2
.
92
6
W
o
rk
in
g 
fo
r p
ay
0.
85
0.
40
, 1
.8
0
.
66
7
SC
Q 
sco
re
1.
09
0.
94
, 1
.2
6
.
24
0
Pr
io
r H
RT
1.
56
0.
51
, 4
.7
5
.
43
3
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
0.
83
0.
38
.1
.8
2
.
63
7
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
1.
54
0.
55
, 4
.2
5
.
41
0
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
1.
31
0.
36
, 4
.8
3
.
68
0
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
1.
05
0.
31
, 3
.5
4
.
94
0
W
ei
gh
t g
ai
n
37
.1
24
.6
O
ve
ra
ll 
M
od
el
X
2 =
17
.0
2;
 p
=.
07
4
M
en
op
au
sa
l s
ta
tu
s*
0.
57
0.
35
, 0
.9
3
.
02
5
0.
94
0.
48
, 1
.8
3
.
84
6
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
0.
87
0.
75
, 1
.0
1
.
06
2
Li
v
es
 a
lo
ne
0.
99
0.
53
, 1
.8
4
.
96
3
W
o
rk
in
g 
fo
r p
ay
0.
99
0.
59
, 1
.6
6
.
98
0
SC
Q 
sco
re
1.
01
0.
92
, 1
.1
2
.
79
8
Pr
io
r H
RT
0.
64
0.
29
, 1
.3
8
.
25
4
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
1.
38
0.
82
, 2
.3
4
.
22
8
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
1.
50
0.
76
, 2
.9
8
.
24
1
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
0.
82
0.
32
, 2
.0
9
.
68
0
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
1.
60
0.
72
, 3
.6
.
25
1
Ir
rit
ab
ili
ty
41
.7
29
.7
O
ve
ra
ll 
M
od
el
X
2 =
12
.2
5;
 p
=.
26
9
M
en
op
au
sa
l s
ta
tu
s
0.
58
0.
36
, 0
.9
4
.
02
7
0.
60
0.
32
, 1
.1
5
.
1 
26
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
0.
94
0.
82
, 1
.0
7
.
34
2
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 21
SY
M
PT
O
M
 O
C
C
U
R
R
EN
C
E
LO
G
IS
TI
C
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
O
cc
ur
re
n
ce
 r
a
te
 %
C
ov
a
ri
at
e
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
PR
E
(n
=1
15
)
PO
ST
(n
=2
12
)
O
R
C
I
p-
va
lu
e
O
R
C
I
p-
va
lu
e
Li
v
es
 a
lo
ne
0.
98
0.
55
, 1
.7
5
.
93
9
W
o
rk
in
g 
fo
r p
ay
0.
93
0.
57
, 1
.5
1
.
76
9
SC
Q 
sco
re
1.
07
0.
98
, 1
.1
7
.
14
4
Pr
io
r H
RT
1.
13
0.
58
, 2
.2
0
.
71
4
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
0.
90
0.
54
, 1
.5
0
.
68
4
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
1.
63
0.
85
, 3
.1
0
.
14
0
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
0.
78
0.
32
, 1
.9
1
.
58
8
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
1.
85
0.
86
, 4
.0
0
.
11
7
Lo
st
 se
x
u
al
 in
te
re
st
22
.4
13
.7
O
ve
ra
ll 
M
od
el
X
2  
=
26
.2
7;
 p
=.
00
3
M
en
op
au
sa
l s
ta
tu
s*
0.
54
0.
30
, 0
.9
8
.
03
9
1.
18
0.
53
, 2
.5
9
.
68
7
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
0.
77
0.
64
, 0
.9
2
.
00
5
Li
v
es
 a
lo
ne
0.
18
0.
05
, 0
.6
0
.
00
5
W
o
rk
in
g 
fo
r p
ay
0.
92
0.
49
, 1
.7
1
.
78
4
SC
Q 
sco
re
1.
03
0.
91
, 1
.1
6
.
68
0
Pr
io
r H
RT
1.
30
0.
53
, 3
.2
.
57
1
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
0.
99
0.
52
, 1
.9
1
.
98
7
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
0.
69
0.
31
, 1
.5
6
.
37
7
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
1.
18
0.
4,
 3
.5
1
.
76
3
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
or 
ma
ste
cto
my
0.
61
0.
22
, 1
.7
2
.
35
3
A
bb
re
v
ia
tio
ns
: C
I =
 c
on
fid
en
ce
 in
te
rv
al
; H
RT
 =
 h
or
m
on
e 
re
pl
ac
em
en
t t
he
ra
py
; O
R 
= 
od
ds
 ra
tio
; P
RE
 =
 p
re
m
en
op
au
sa
l; 
PO
ST
 =
 p
os
tm
en
op
au
sa
l; 
re
f =
 re
fe
re
nc
e 
gr
ou
p;
 S
CQ
 = 
Se
lf-
ad
mi
nis
ter
ed
 
Co
m
or
bi
di
ty
 Q
ue
sti
on
na
ire
; v
s =
 ve
rs
u
s
*
re
fe
re
nc
e 
gr
ou
p 
= 
pr
em
en
op
au
sa
l w
o
m
en
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 22
Ta
bl
e 
4
R
es
ul
ts 
of
 u
na
dju
ste
d a
nd
 ad
jus
ted
 lo
gis
tic
 re
gr
es
sio
n 
an
al
ys
es
 th
at
 ev
al
ua
te
d 
fo
r d
iff
er
en
ce
s b
et
w
ee
n 
pr
em
en
op
au
sa
l a
nd
 p
os
tm
en
op
au
sa
l w
o
m
en
 in
 
sy
m
pt
om
 o
cc
ur
re
nc
e 
ra
te
s w
ith
 in
te
ra
ct
io
n 
ef
fe
ct
s 1
2 
m
on
th
s a
fte
r b
re
as
t c
an
ce
r s
ur
ge
ry
LO
G
IS
TI
C
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
C
ov
a
ri
at
es
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
O
R
C
I
p-
va
lu
e
O
R
C
I
p-
va
lu
e
Lo
gi
st
ic
 R
eg
re
ss
io
n 
R
es
ul
ts
 fo
r 
To
ta
l S
am
pl
e
H
ot
 fl
as
he
s
PR
E 
= 
58
.3
%
PO
ST
 =
 4
5.
3%
O
ve
ra
ll 
M
od
el
X
2 =
59
.5
3;
 p
<.
00
1
M
en
op
au
sa
l s
ta
tu
s*
0.
56
0.
35
, 0
.8
9
.
01
5
56
81
.1
2
13
6.
43
, 2
36
57
6.
94
<
.0
01
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
1.
38
1.
00
, 1
.9
2
.
05
0
Li
v
es
 a
lo
ne
0.
92
0.
51
, 1
.6
5
.
77
0
W
o
rk
in
g 
fo
r p
ay
0.
65
0.
39
, 1
.0
7
.
08
9
SC
Q 
sco
re
1.
07
0.
97
, 1
.1
7
.
18
8
Pr
io
r H
RT
2.
19
1.
1 
0,
 4
.3
6
.
02
6
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
1.
11
0.
66
, 1
.8
7
.
69
2
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
1.
11
0.
59
, 2
.1
 0
.
73
9
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
1.
52
0.
63
, 3
.6
8
.
35
2
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
0.
96
0.
44
, 2
.1
 0
.
92
1
A
ge
 ×
 m
en
op
au
sa
l s
ta
tu
s
0.
42
0.
29
, 0
.6
1
.
00
0
A
dju
ste
d R
eg
re
ss
io
n 
of
 H
ot
 F
la
sh
es
 O
cc
ur
re
nc
e 
on
 A
ge
, S
tra
tif
ie
d 
by
 M
en
op
au
sa
l S
ta
tu
s
Pr
em
en
op
au
sa
l
1.
43
0.
99
, 2
.0
6
.
05
5
Po
st
m
en
op
au
sa
l
0.
56
0.
46
, 0
.6
9
<
.0
01
N
ig
ht
 S
w
ea
ts
PR
E 
= 
44
.3
%
PO
ST
 =
 3
2.
5%
O
ve
ra
ll 
M
od
el
X
2 =
41
.7
0;
 p
<.
00
1
M
en
op
au
sa
l s
ta
tu
s*
0.
59
0.
37
, 0
.9
4
.
02
6
11
32
.5
0
29
.3
8,
 4
36
55
.1
<
.0
01
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
1.
3 
0
0.
94
, 1
.8
 0
.
11
7
Li
v
es
 a
lo
ne
1.
05
0.
57
, 1
.9
2
.
87
2
W
o
rk
in
g 
fo
r p
ay
0.
97
0.
59
, 1
.5
9
.
89
2
SC
Q 
sco
re
1.
04
0.
95
, 1
.1
5
.
39
7
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 23
LO
G
IS
TI
C
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
C
ov
a
ri
at
es
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
O
R
C
I
p-
va
lu
e
O
R
C
I
p-
va
lu
e
Pr
io
r H
RT
2.
35
1.
18
, 4
.6
7
.
01
5
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
1.
04
0.
62
, 1
.7
5
.
87
2
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
0.
85
0.
45
, 1
.6
2
.
63
2
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
0.
91
0.
38
, 2
.2
 0
.
83
7
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
1.
28
0.
58
, 2
.8
2
.
53
6
A
ge
 ×
 m
en
op
au
sa
l s
ta
tu
s
0.
49
0.
34
, 0
.7
1
<
.0
01
A
dju
ste
d R
eg
re
ss
io
n 
of
 N
ig
ht
 S
w
ea
ts 
O
cc
ur
re
nc
e 
on
 A
ge
, S
tra
tif
ie
d 
by
 M
en
op
au
sa
l S
ta
tu
s
Pr
em
en
op
au
sa
l
1.
31
0.
92
, 1
.8
8
.
14
0
Po
st
m
en
op
au
sa
l
0.
63
0.
52
, 0
.7
6
<
.0
01
D
ep
re
ss
io
n
PR
E 
= 
34
.5
%
PO
ST
 =
 2
4.
5%
O
ve
ra
ll 
M
od
el
X
2  
=
30
.9
2;
 p
=.
00
1
M
en
op
au
sa
l s
ta
tu
s*
0.
60
0.
37
, 0
.9
9
.
04
7
33
8.
93
6.
92
, 1
66
11
.1
6
.
00
3
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
1.
41
0.
98
, 2
.0
2
.
06
1
Li
v
es
 a
lo
ne
0.
89
0.
47
, 1
.7
1
.
73
3
W
o
rk
in
g 
fo
r p
ay
1.
02
0.
60
, 1
.7
3
.
93
7
SC
Q 
sco
re
1.
18
1.
07
, 1
.3
0
.
00
1
Pr
io
r H
RT
0.
83
0.
39
, 1
.7
6
.
62
0
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
1.
04
0.
60
, 1
.7
9
.
88
9
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
0.
82
0.
42
, 1
.6
1
.
57
1
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
1.
19
0.
47
, 2
.9
8
.
71
7
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
1.
16
0.
51
, 2
.6
4
.
72
5
A
ge
 ×
 m
en
op
au
sa
l s
ta
tu
s
0.
54
0.
36
, 0
.8
 0
.
00
2
A
dju
ste
d R
eg
re
ss
io
n 
of
 D
ep
re
ss
io
n 
O
cc
ur
re
nc
e 
on
 A
ge
, S
tra
tif
ie
d 
by
 M
en
op
au
sa
l S
ta
tu
s
Pr
em
en
op
au
sa
l
1.
50
1.
00
, 2
.2
5
.
04
8
Po
st
m
en
op
au
sa
l
0.
77
0.
64
, 0
.9
2
.
00
3
D
ay
tim
e 
sw
ea
ts
PR
E 
= 
39
.7
%
PO
ST
 =
 2
6.
9%
O
ve
ra
ll 
M
od
el
X
2 =
34
.5
35
; p
=.
01
1
M
en
op
au
sa
l s
ta
tu
s*
0.
53
0.
33
, 0
.8
7
.
01
1
13
7.
20
3.
53
, 5
32
9.
31
.
00
8
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 24
LO
G
IS
TI
C
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
C
ov
a
ri
at
es
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
O
R
C
I
p-
va
lu
e
O
R
C
I
p-
va
lu
e
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
1.
3 
0
0.
93
, 1
.8
3
.
12
1
Li
v
es
 a
lo
ne
0.
78
0.
42
, 1
.4
7
.
44
6
W
o
rk
in
g 
fo
r p
ay
0.
91
0.
54
, 1
.5
1
.
70
5
SC
Q 
sco
re
1.
08
0.
98
, 1
.1
9
.
12
2
Pr
io
r H
RT
2.
92
1.
46
, 5
.8
3
.
00
2
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
0.
98
0.
57
, 1
.6
6
.
93
1
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
1.
21
0.
61
, 2
.3
9
.
58
1
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
0.
62
0.
24
, 1
.5
6
.
30
8
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
2.
18
0.
97
, 4
.9
3
.
06
0
A
ge
 ×
 m
en
op
au
sa
l s
ta
tu
s
0.
57
0.
39
, 0
.8
3
.
00
4
A
dju
ste
d R
eg
re
ss
io
n 
of
 D
ay
tim
e 
Sw
ea
ts 
O
cc
ur
re
nc
e 
on
 A
ge
, S
tra
tif
ie
d 
by
 M
en
op
au
sa
l S
ta
tu
s
Pr
em
en
op
au
sa
l
1.
27
0.
89
, 1
.8
1
.
19
0
Po
st
m
en
op
au
sa
l
0.
74
0.
63
, 0
.8
9
.
00
1
Jo
in
t p
ai
n 
or
 st
iff
ne
ss
PR
E 
= 
40
.0
%
PO
ST
 =
 5
1.
9%
O
ve
ra
ll 
M
od
el
X
2 =
23
.6
6;
 p
=.
01
4
M
en
op
au
sa
l s
ta
tu
s*
1.
62
1.
02
, 2
.5
7
.
04
3
38
7.
32
6.
64
, 2
26
01
.8
0
.
00
4
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
1.
88
1.
26
, 2
.7
9
.
00
2
Li
v
es
 a
lo
ne
0.
97
0.
56
, 1
.6
8
.
90
6
W
o
rk
in
g 
fo
r p
ay
0.
89
0.
55
, 1
.4
2
.
61
4
SC
Q 
sco
re
1.
07
0.
98
, 1
.1
7
.
13
3
Pr
io
r H
RT
1.
00
0.
54
, 1
.8
6
.
99
3
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
1.
40
0.
85
, 2
.3
2
.
18
8
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
0.
63
0.
34
, 1
.1
7
.
14
5
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
1.
31
0.
54
, 3
.1
6
.
55
1
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
0.
61
0.
28
, 1
.3
1
.
20
6
A
ge
 ×
 m
en
op
au
sa
l s
ta
tu
s
0.
54
0.
36
, 0
.8
3
.
00
4
A
dju
ste
d R
eg
re
ss
io
n 
of
 Jo
in
t P
ai
n 
O
cc
ur
re
nc
e 
on
 A
ge
, S
tra
tif
ie
d 
by
 M
en
op
au
sa
l S
ta
tu
s
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 25
LO
G
IS
TI
C
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
C
ov
a
ri
at
es
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
O
R
C
I
p-
va
lu
e
O
R
C
I
p-
va
lu
e
Pr
em
en
op
au
sa
l
2.
07
1.
33
, 3
.2
3
.
00
1
Po
st
m
en
op
au
sa
l
1.
00
0.
86
, 1
.1
5
.
94
7
W
ak
e 
du
rin
g 
th
e 
ni
gh
t
PR
E 
= 
61
.7
%
PO
ST
 =
 6
3.
7%
O
ve
ra
ll 
M
od
el
X
2 =
23
.1
2;
 p
=.
01
7
M
en
op
au
sa
l s
ta
tu
s*
1.
08
0.
67
, 1
.7
3
.
76
4
14
9.
89
4.
59
, 4
89
3.
95
.
00
5
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
1.
25
0.
91
, 1
.7
2
.
17
0
Li
v
es
 a
lo
ne
0.
92
0.
52
, 1
.6
3
.
77
9
W
o
rk
in
g 
fo
r p
ay
0.
64
0.
39
, 1
.0
5
.
07
9
SC
Q 
sco
re
1.
10
1.
00
, 1
.2
1
.
05
8
Pr
io
r H
RT
1.
29
0.
67
, 2
.4
8
.
44
7
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
0.
90
0.
53
, 1
.5
1
.
67
8
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
1.
06
0.
57
, 1
.9
7
.
85
5
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
2.
53
0.
99
, 6
.4
7
.
05
2
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
0.
7 
0
0.
32
, 1
.5
4
.
38
0
A
ge
 ×
 m
en
op
au
sa
l s
ta
tu
s
0.
62
0.
44
, 0
.8
8
.
00
8
A
dju
ste
d R
eg
re
ss
io
n 
of
 W
ak
e 
D
ur
in
g 
th
e 
N
ig
ht
 O
cc
ur
re
nc
e 
on
 A
ge
, S
tra
tif
ie
d 
by
 M
en
op
au
sa
l S
ta
tu
s
Pr
em
en
op
au
sa
l
1.
29
0.
92
, 1
.8
0
.
14
2
Po
st
m
en
op
au
sa
l
0.
76
0.
64
, 0
.9
0
.
00
1
N
um
bn
es
s o
r t
in
gl
in
g
PR
E 
= 
27
.8
%
PO
ST
 =
 2
9.
7%
O
ve
ra
ll 
M
od
el
X
2 =
29
.3
7;
 p
=.
00
2
M
en
op
au
sa
l s
ta
tu
s*
1.
12
0.
67
, 1
.8
6
.
67
3
17
4.
64
3.
33
, 9
17
1.
79
.
01
1
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
1.
29
0.
89
, 1
.8
7
.
18
5
Li
v
es
 a
lo
ne
1.
52
0.
83
, 2
.7
9
.
17
4
W
o
rk
in
g 
fo
r p
ay
0.
74
0.
44
, 1
.2
4
.
25
3
SC
Q 
sco
re
1.
08
0.
98
, 1
.1
8
.
14
3
Pr
io
r H
RT
1.
05
0.
52
, 2
.1
2
.
90
0
A
dju
va
n
t c
he
m
ot
he
ra
py
 d
ur
in
g 
12
 m
on
th
s
2.
47
1.
45
, 4
.2
0
.
00
1
R
ad
ia
tio
n 
th
er
ap
y 
du
rin
g 
12
 m
on
th
s
0.
82
0.
42
, 1
.6
 0
.
56
2
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 26
LO
G
IS
TI
C
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
C
ov
a
ri
at
es
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
O
R
C
I
p-
va
lu
e
O
R
C
I
p-
va
lu
e
R
ec
on
st
ru
ct
io
n 
du
rin
g 
12
 m
on
th
s
1.
06
0.
42
, 2
.6
7
.
90
5
Ty
pe
 o
f s
ur
ge
ry
: c
on
se
rv
at
io
n 
(re
f) 
vs
 m
ast
ec
tom
y
1.
16
0.
52
, 2
.6
 0
.
71
0
A
ge
 ×
 m
en
op
au
sa
l s
ta
tu
s
0.
62
0.
41
, 0
.9
2
.
01
9
A
dju
ste
d R
eg
re
ss
io
n 
of
 N
um
bn
es
s o
r T
in
gl
in
g 
O
cc
ur
re
nc
e 
on
 A
ge
, S
tra
tif
ie
d 
by
 M
en
op
au
sa
l S
ta
tu
s
Pr
em
en
op
au
sa
l
1.
32
0.
88
, 1
.9
8
.
17
6
Po
st
m
en
op
au
sa
l
0.
79
0.
66
, 0
.9
3
.
00
6
A
bb
re
v
ia
tio
ns
: C
I =
 c
on
fid
en
ce
 in
te
rv
al
; H
RT
 =
 h
or
m
on
e 
re
pl
ac
em
en
t t
he
ra
py
; O
R 
= 
od
ds
 ra
tio
; P
RE
 =
 p
re
m
en
op
au
sa
l; 
PO
ST
 =
 p
os
tm
en
op
au
sa
l; 
re
f =
 re
fe
re
nc
e 
gr
ou
p;
 S
CQ
 = 
Se
lf-
ad
mi
nis
ter
ed
 
Co
m
or
bi
di
ty
 Q
ue
sti
on
na
ire
; v
s =
 ve
rs
u
s
*
re
fe
re
nc
e 
gr
ou
p 
= 
pr
em
en
op
au
sa
l w
o
m
en
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 27
Ta
bl
e 
5
R
es
ul
ts 
of
 u
na
dju
ste
d a
nd
 ad
jus
ted
 lin
ear
 re
gr
es
sio
n 
an
al
ys
es
 th
at
 ev
al
ua
te
d 
fo
r d
iff
er
en
ce
s i
n 
sy
m
pt
om
 se
v
er
ity
 a
nd
 d
ist
re
ss
 sc
or
es
 b
et
w
ee
n 
pr
em
en
op
au
sa
l a
nd
 p
os
tm
en
op
au
sa
l w
o
m
en
 1
2 
m
on
th
s a
fte
r s
ur
ge
ry
SY
M
PT
O
M
LI
N
EA
R
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
Se
v
er
ity
 S
co
re
 (0
–1
0)
M
ea
n 
(S
D)
C
ov
a
ri
at
e
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
Pr
em
en
Po
st
m
en
B
C
I
p-
va
lu
e
B
C
I
p-
va
lu
e
SY
M
PT
O
M
 S
EV
ER
IT
Y
Fa
tig
ue
4.
7 
(2.
6)
3.
8 
(2.
4)
O
ve
ra
ll 
M
od
el
F=
2.
11
; R
2 =
.1
2;
 p
=.
02
7
M
en
op
au
sa
l s
ta
tu
s*
−
0.
73
−
1.
51
, 0
.0
6
.
07
1
−
1.
00
−
1.
98
, −
0.
01
.
04
8
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
−
0.
15
−
0.
36
, 0
.0
6
.
16
3
Li
v
es
 a
lo
ne
0.
36
−
0.
55
, 1
.2
7
.
43
7
W
o
rk
in
g 
fo
r p
ay
−
0.
58
−
1.
35
, 0
.1
9
.
14
0
SC
Q 
sco
re
0.
19
0.
05
, 0
.3
4
.
00
8
Pr
io
r H
RT
0.
29
−
0.
74
, 1
.3
1
.
58
0
A
ny
 a
dju
va
n
t c
he
m
ot
he
ra
py
 in
 p
as
t 1
2 
m
on
th
s
0.
40
−
0.
42
, 1
.2
3
.
33
6
A
ny
 a
dju
va
n
t r
ad
ia
tio
n 
th
er
ap
y 
in
 p
as
t 1
2 
m
on
th
s
0.
50
−
0.
43
, 1
.4
4
.
29
0
A
ny
 b
re
as
t r
ec
on
str
uc
tio
ns
 m
on
th
s i
n 
pa
st 
12
 m
on
th
s
−
0.
24
−
1.
58
, 1
.1
1
.
72
9
Ty
pe
 o
f s
ur
ge
ry
: l
um
pe
ct
om
y 
(re
f) 
vs
 m
ast
ec
tom
y
−
0.
30
−
1.
47
, 0
.8
8
.
61
6
Im
pa
tie
nc
e
3.
8 
(2.
3)
2.
7 
(1.
8)
O
ve
ra
ll 
M
od
el
F=
2.
22
; R
2 =
.1
7;
 p
=.
02
2
M
en
op
au
sa
l s
ta
tu
s*
−
1.
15
−
1.
88
, −
0.
42
.
00
2
−
0.
89
−
1.
80
, 0
.0
2
.
05
5
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
−
0.
12
−
0.
30
, 0
.0
7
.
22
7
Li
v
es
 a
lo
ne
−
0.
31
−
1.
20
, 0
.5
8
.
48
6
W
o
rk
in
g 
fo
r p
ay
−
0.
18
−
0.
92
, 0
.5
6
.
63
9
SC
Q 
sco
re
0.
14
−
0.
01
, 0
.2
9
.
06
1
Pr
io
r H
RT
−
0.
12
−
1.
16
, 0
.9
2
.
81
6
A
ny
 a
dju
va
n
t c
he
m
ot
he
ra
py
 in
 p
as
t 1
2 
m
on
th
s
0.
66
−
0.
11
, 1
.4
3
.
09
1
A
ny
 a
dju
va
n
t r
ad
ia
tio
n 
th
er
ap
y 
in
 p
as
t 1
2 
m
on
th
s
0.
20
−
0.
74
, 1
.1
4
.
67
8
A
ny
 b
re
as
t r
ec
on
str
uc
tio
ns
 m
on
th
s i
n 
pa
st 
12
 m
on
th
s
0.
66
−
0.
63
, 1
.9
5
.
31
3
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 28
SY
M
PT
O
M
LI
N
EA
R
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
Se
v
er
ity
 S
co
re
 (0
–1
0)
M
ea
n 
(S
D)
C
ov
a
ri
at
e
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
Pr
em
en
Po
st
m
en
B
C
I
p-
va
lu
e
B
C
I
p-
va
lu
e
Ty
pe
 o
f s
ur
ge
ry
: l
um
pe
ct
om
y 
(re
f) 
vs
 m
ast
ec
tom
y
−
0.
76
−
1.
90
, 0
.3
9
.
19
4
Ir
rit
ab
ili
ty
3.
8 
(2.
4)
2.
9 
(1.
9)
O
ve
ra
ll 
M
od
el
F=
3.
81
; R
2 =
.2
8;
 p
<.
00
1
M
en
op
au
sa
l s
ta
tu
s*
−
1.
10
−
1.
91
, −
0.
30
.
00
8
−
0.
56
−
1.
46
, 0
.3
4
.
21
9
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
−
0.
32
−
0.
52
, −
0.
12
.
00
2
Li
v
es
 a
lo
ne
0.
11
−
0.
81
, 1
.0
3
.
81
4
W
o
rk
in
g 
fo
r p
ay
−
0.
31
−
1.
09
, 0
.4
7
.
42
8
SC
Q 
sco
re
0.
29
0.
14
, 0
.4
5
<
.0
01
Pr
io
r H
RT
−
0.
08
−
1.
17
, 1
.0
1
.
88
8
A
ny
 a
dju
va
n
t c
he
m
ot
he
ra
py
 in
 p
as
t 1
2 
m
on
th
s
0.
66
−
0.
17
, 1
.4
8
.
11
9
A
ny
 a
dju
va
n
t r
ad
ia
tio
n 
th
er
ap
y 
in
 p
as
t 1
2 
m
on
th
s
0.
26
−
0.
70
, 1
.2
2
.
59
6
A
ny
 b
re
as
t r
ec
on
str
uc
tio
ns
 m
on
th
s i
n 
pa
st 
12
 m
on
th
s
0.
86
−
0.
45
, 2
.1
7
.
19
4
Ty
pe
 o
f s
ur
ge
ry
: l
um
pe
ct
om
y 
(re
f) 
vs
 m
ast
ec
tom
y
−
0.
32
−
1.
4,
 0
.7
5
.
55
1
SY
M
PT
O
M
 D
IS
TR
ES
S
Sy
m
pt
om
D
ist
re
ss
 S
co
re
 (0
–1
0)
M
ea
n 
(S
D)
Co
v
ar
ia
te
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
PR
E
PO
ST
B
CI
p-
va
lu
e
B
CI
p-
va
lu
e
Im
pa
tie
nc
e
3.
9 
(2.
9)
2.
6 
(2.
0)
O
ve
ra
ll 
M
od
el
F=
2.
01
; R
2 =
.1
5;
 p
=.
03
9
M
en
op
au
sa
l s
ta
tu
s*
−
1.
29
−
2.
17
, −
0.
40
.
00
5
−
0.
69
−
1.
79
, 0
.4
1
.
21
7
A
ge
 (i
n 5
 ye
ar 
inc
rem
en
ts)
−
0.
18
−
0.
42
, 0
.0
5
.
13
1
Li
v
es
 a
lo
ne
−
0.
59
−
1.
68
, 0
.5
0
.
28
3
W
o
rk
in
g 
fo
r p
ay
−
0.
28
−
1.
18
, 0
.6
1
.
53
2
SC
Q 
sco
re
0.
14
−
0.
04
, 0
.3
2
.
13
4
Pr
io
r H
RT
−
0.
6 
0
−
1.
87
, 0
.6
8
.
35
4
A
ny
 a
dju
va
n
t c
he
m
ot
he
ra
py
 in
 p
as
t 1
2 
m
on
th
s
0.
53
−
0.
41
, 1
.4
6
.
26
6
A
ny
 a
dju
va
n
t r
ad
ia
tio
n 
th
er
ap
y 
in
 p
as
t 1
2 
m
on
th
s
−
0.
09
−
1.
25
, 1
.0
8
.
88
4
A
ny
 b
re
as
t r
ec
on
str
uc
tio
ns
 m
on
th
s i
n 
pa
st 
12
 m
on
th
s
0.
65
−
0.
92
, 2
.2
2
.
41
3
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mazor et al. Page 29
SY
M
PT
O
M
LI
N
EA
R
 R
EG
R
ES
SI
O
N
 R
ES
U
LT
S
Sy
m
pt
om
Se
v
er
ity
 S
co
re
 (0
–1
0)
M
ea
n 
(S
D)
C
ov
a
ri
at
e
U
na
dju
ste
d M
od
el
A
dju
ste
d M
od
el
Pr
em
en
Po
st
m
en
B
C
I
p-
va
lu
e
B
C
I
p-
va
lu
e
Ty
pe
 o
f s
ur
ge
ry
: l
um
pe
ct
om
y 
(re
f) 
vs
 m
ast
ec
tom
y
−
0.
65
−
2.
05
, 0
.7
5
.
36
 0
A
bb
re
v
ia
tio
ns
: B
 =
 B
et
a 
co
ef
fic
ie
nt
; C
I =
 c
on
fid
en
ce
 in
te
rv
al
; H
RT
 =
 h
or
m
on
e 
re
pl
ac
em
en
t t
he
ra
py
; P
re
m
en
 =
 p
re
m
en
op
au
sa
l; 
Po
stm
en
 =
 p
os
tm
en
op
au
sa
l; 
re
f =
 re
fe
re
nc
e 
gr
ou
p;
 S
CQ
 = 
Se
lf-
ad
mi
nis
ter
ed
 
Co
m
or
bi
di
ty
 Q
ue
sti
on
na
ire
; v
s =
 ve
rs
u
s
*
re
fe
re
nc
e 
gr
ou
p 
= 
pr
em
en
op
au
sa
l w
o
m
en
J Pain Symptom Manage. Author manuscript; available in PMC 2019 April 01.
